Skip to main content
. 2012 Apr 19;7(4):e35130. doi: 10.1371/journal.pone.0035130

Figure 5. Antitumor activity of MTM-SDK and MTM-SK in subcutaneous prostate tumor xenografts.

Figure 5

Mice with subcutaneous tumors were treated with the indicated doses of MTM-SDK, MTM-SK or sterile saline solution (control) given by IP injections twice a week for five weeks (q3d×10). Tumor volume (A) and body weight (B) were measured twice a week. Results are expressed as mean ± SD of the tumor volume in each group. Arrows indicate start and end of the treatment. **, P<0.001.